Skoči na glavni sadržaj

Izvorni znanstveni članak

Four-year Study of Entecavir Efficacy and Safety in Nucleos(T)ide-naive HBeAg Positive Chronic Hepatitis B Patients

Mustafa Kemal Celen
Tuba Dal
Celal Ayaz
Kadim Bayan
Duygu Mert
Ozcan Deveci
Ebru Kursun Oruc


Puni tekst: engleski pdf 123 Kb

verzije

str. 31-36

preuzimanja: 618

citiraj


Sažetak

Entecavir is a guanosine analogue with activity against hepatitis B virus. The aim of this 4-year trial was to evaluate entecavir treatment in nucleos(t)ide-naive HBeAg-positive chronic hepatitis B patients. Forty-nine patients received entecavir and nine of them withdrew from the trial at the end of week 96. The initial mean value of alanine aminotransferase was 79.4}41.5 IU /L, and at the end of the 4-year study period, 90% of patients had alanine aminotransferase values within the normal range. At week 96, 91.7% of patients had HBV DNA <300 copies; at month 48, 90% of patients had HBV DNA <50 IU /mL. HBeAg loss was recorded in 7.1% of patients at week 96 and in 12.5% at month 48. The rate of HBeAg seroconversion was 4.8% at week 96 and 7.5% at month 48. The rate of HBsAg seroconversion was 2.1% at week 96 and 2.5% at month 48. Entecavir as a potent and safe agent leading to continuous viral suppression proved to be safe and well tolerated therapy.

Ključne riječi

Guanine – therapeutic use; Hepatitis B, chronic; Antiviral agents – therapy

Hrčak ID:

126146

URI

https://hrcak.srce.hr/126146

Datum izdavanja:

1.3.2014.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.445 *